Shares in Gina-Rinehart-backed G50 Corp Ltd (ASX: G50) are trading about 50% below their highs over the past year, but the team at Morgans believes the shares are ripe for a rerating.

The broker has issued a research note to its clients with a speculative buy recommendation on the shares and a very bullish share price target, which I’ll get to shortly.

What’s so special about this ASX explorer?

One of the reasons for their confidence in the exploration company is the backing of iron ore magnate Ms Rinehart, whose company Hancock Prospecting invested $7.95 million into G50 as part of a recent share placement, emerging with a 5.4% stake.

The $26.25 million which was raised at 59.5 cents per share – the shares are currently changing hands for 49.5 cents – is to be used to accelerate exploration at the company’s Golconda Project in Arizona and its White Caps Project in Nevada.

The work will include further drilling, geological studies, gallium test work, and early permitting activities at Golconda.

Chair Ian Davies said regarding the placement:

We’re pleased to welcome Hancock Prospecting to the register as a cornerstone investor. Hancock is one of Australia’s most respected resources investors, and their decision to back a company whose assets sit entirely in the United States, across both precious metals and strategic minerals, is a meaningful endorsement of the work Mark and the team have done at Golconda and White Caps. The board’s focus is now on deploying this capital with discipline against the program we’ve set out and on the drilling and metallurgical test work that will ultimately determine the value of both projects.

Shares looking cheap, broker says

Morgans said recent drilling results had extended the strike length at Golconda to 1.8km, and there had also been a high-grade gold discovery at White Caps.

They added that metallurgical test work had confirmed the potential to generate a gallium-rich precious metals concentrate at Golconda through conventional processing methods.

The broker added:

We view Hancock’s investment as a strong endorsement of the G50 story, in particular its strategy to unlock and monetise its Golconda gallium. Hancock has taken a selective approach in recent years, deploying capital offshore and across the broader critical minerals thematic, taking substantial positions in names such as St George Mining, Vulcan Energy and MP Materials. We think Hancock’s due diligence of the project, capacity to support further funding and diversification into North America are all very supportive of the factors which differentiate G50 from other precious metals exposures.

Morgans said G50 was well-funded for 18 to 24 months. The broker has a price target on G50 shares of $1.94.

The company is valued at $118.4 million.

The post This Gina Rinehart-backed ASX explorer could rise almost 300%, Morgans says appeared first on The Motley Fool Australia.

More reading

• 8 ASX shares upgraded by the professionals post-results this week
• Up 20% this year, are Rio Tinto shares still good value?
• Why I’m still smiling after losing 85%
• Why brokers see 85% upside for this ASX biotech stock
• Down another 18%: Why I’d buy WiseTech shares in the dip

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Mesoblast Ltd (ASX: MSB) shares have been sluggish in 2026, falling around 12% so far. However, the ASX biotech stock is showing signs of life, with shares up around 1% to $2.40 in early Friday afternoon trading. This is taking their monthly gain to 15% and their 12-month return to 25%.

Could another leg higher be coming?

Ryoncil is turning Mesoblast commercial

Mesoblast develops and commercialises allogeneic cellular medicines for complex diseases. The big change for the ASX biotech stock is that it is no longer simply a clinical-stage biotech, with its Ryoncil product now approved in the US and generating meaningful revenue.

Ryoncil treats children with steroid-refractory acute graft-versus-host disease, a serious complication that can occur after a stem cell transplant. The product generated US$115 million in net revenue during FY2026, its first full year following launch, with fourth-quarter revenue reaching US$36 million, up 20% from the previous quarter.

Mesoblast is now working to expand Ryoncil into adults with the same condition, potentially opening up a market around three times larger than the paediatric opportunity. The company has commenced its registration trial and is planning a broad US clinical program.

There are further opportunities in the pipeline. Mesoblast is developing Ryoncil for Duchenne muscular dystrophy, with the US Food and Drug Administration having cleared the company to proceed with a registrational trial.

More catalysts in the making

The company also has potentially significant catalysts beyond Ryoncil. Its rexlemestrocel-L therapy is being developed for chronic lower back pain. The opportunity is what makes this trial particularly interesting for the ASX biotech stock.

The company estimates that chronic lower back pain associated with inflammation and degenerative disc disease affects more than 7 million people in the US. Even single-digit market penetration could potentially generate peak annual revenue of more than US$10 billion, according to Mesoblast.

However, investors will have to wait. Top-line results are expected around the middle of 2027, after the final patient completes 12 months of follow-up.

Brokers see plenty more upside

That pipeline is helping fuel optimism among brokers.

TradingView data shows all six analysts covering the ASX biotech stock rate it a strong buy. Their average price target of $4.27 implies potential upside of approximately 78% from $2.40. The most bullish forecast is $5.46, representing around 128% upside, while the most pessimistic is $2.90.

Bell Potter is particularly bullish. The broker retained its buy rating and $4.45 price target following Mesoblast’s latest results. It expects continued double-digit growth from Ryoncil, alongside major potential catalysts from rexlemestrocel-L in heart failure and chronic lower back pain.

At $4.45, Bell Potter’s price target implies approximately 85% upside from the current $2.40 share price.

For investors comfortable with biotech risk, Mesoblast offers an increasingly interesting proposition: a commercial product generating meaningful revenue, an expanding pipeline and significant potential upside if its key clinical programs continue to progress.

The post Why brokers see 85% upside for this ASX biotech stock appeared first on The Motley Fool Australia.

More reading

• Experts tip these $3 billion ASX shares to deliver over 75% returns
• Buy, hold, sell: Challenger, APA Group, Mesoblast shares
• Why now is the time to buy low on these ASX healthcare shares with up to 84% upside
• Mesoblast earnings: Strong revenue growth and operational milestones in FY26
• ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus

Motley Fool contributor Marc Van Dinther has positions in Mesoblast. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

WiseTech Global Ltd (ASX: WTC) shares have climbed into the green in Friday lunchtime trade.

At the time of writing, the ASX tech shares are up around 1%, and are changing hands for $37.02 a piece.

Today’s increase is good news for investors, but it barely makes a dent in the huge amount of losses shed so far this year.

The shares are now down 46% year to date and around 61% lower than a year ago.

What happened to WiseTech shares?

WiseTech shares were smashed by a tech sector-wide sell-off and an investor rotation to more stable assets amid global volatility earlier this year. 

The company’s shares have also come under pressure this year following a series of updates and media reports surrounding investigations into founder Richard White by the Australian Federal Police and recent news that the Australian Competition and Consumer Commission (ACCC) executed a search warrant on the company 

ASIC and the AFP also searched WiseTech Global’s headquarters in late October 2025.

More recently, investors rotated away from the stock after it posted its FY26 results late last month.

WiseTech reported that it has raised its annual earnings and flagged growth for FY27 in line with analysts’ expectations.

The company reported a 46% increase in EBITDA to US$558.4 million for the 12 months through to the 30th of June. The result was in line with the company’s $550 million to $585 million guidance range but short of market forecasts of $569.5 million.

Investors weren’t impressed and quickly sold up their shares. WiseTech shares have now tumbled over 18% since it posted its results.

Why I’d buy WiseTech shares in the dip

It’s been headwind after headwind for the tech company this year, and investor confidence has dwindled.

But WiseTech has a strong competitive advantage in the global logistics industry and strong growth prospects. 

The company’s CargoWise platform is deeply embedded in the global logistics industry. It is difficult to replace, and this gives WiseTech a strong competitive advantage in the global logistics industry.

If global trade volumes keep expanding and supply chains become more digital, WiseTech could become a dominant software provider in the logistics industry.

CEO Zubin Appoo has also previously commented that AI is actually strengthening the company’s advantage in the market. Rather than replacing the need for WiseTech’s subscription-based software, he said the company’s AI capabilities work to unlock efficiency gains and add value to customers. This is another strong tailwind for the business.

Let’s also remember that the company’s FY26 results came in line with its guidance figures, and a 46% increase in EBITDA shows that the business is performing well.

After the latest share price sell-off, the shares look significantly undervalued to me.

And it looks like brokers are also confident that WiseTech could still be a turnaround story.

What do brokers tip for the ASX tech stock next?

Market Index shows that all brokers are very bullish on the ASX tech stock and hold a strong buy rating. The average $61.19 target price implies a potential 66% upside over the next 12 months, at the time of writing. 

Most interestingly, this is a significant increase from just a week ago. Immediately following WiseTech’s results announcement, brokers were more divided, and the average target price was much lower at $54.71.

TradingView data also shows that brokers are much more positive following the company’s results announcement. Of 17 analysts, 13 have a buy/strong buy rating.

The average target price is largely unchanged, at $57.19. This implies a potential 56% upside over the next 12 months, at the time of writing.

If forecasts come to fruition, it looks like now is a great time to buy the shares in the dip while they’re still trading for cheap.

The post Down another 18%: Why I’d buy WiseTech shares in the dip appeared first on The Motley Fool Australia.

More reading

• Where could the WiseTech share price be in 12 months?
• 40 ASX shares with ex-dividend dates next week
• Are these ASX tech stocks finally a buy again?
• WiseTech shares are turning red again. Is the rally over?
• Why I think Zip and WiseTech shares could be buys in September

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.